Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-0.89 Insider Own1.00% Shs Outstand144.91M Perf Week-0.52%
Market Cap7.79B Forward P/E- EPS next Y-0.58 Insider Trans243.07% Shs Float142.23M Perf Month-5.25%
Income-125.50M PEG- EPS next Q-0.42 Inst Own94.50% Short Float8.60% Perf Quarter-8.38%
Sales482.30M P/S16.16 EPS this Y11.90% Inst Trans2.80% Short Ratio10.15 Perf Half Y13.22%
Book/sh4.70 P/B11.44 EPS next Y63.10% ROA-15.30% Target Price66.38 Perf Year-16.72%
Cash/sh2.85 P/C18.87 EPS next 5Y- ROE-20.00% 52W Range45.31 - 71.32 Perf YTD0.52%
Dividend- P/FCF- EPS past 5Y-14.00% ROI-24.00% 52W High-24.59% Beta1.97
Dividend %- Quick Ratio3.10 Sales past 5Y18.00% Gross Margin88.80% 52W Low18.69% ATR2.03
Employees1100 Current Ratio3.50 Sales Q/Q23.10% Oper. Margin-40.60% RSI (14)50.52 Volatility2.85% 3.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-5.70% Profit Margin-26.00% Rel Volume0.77 Prev Close54.11
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume1.21M Price53.78
Recom2.30 SMA20-0.41% SMA50-0.55% SMA200-4.33% Volume924,206 Change-0.61%
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Feb-07-18Reiterated Needham Buy $72 → $74
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Oct-24-17Resumed Guggenheim Buy $72
Oct-20-17Upgrade Barclays Equal Weight → Overweight $60 → $70
Oct-06-17Resumed Goldman Neutral
Sep-15-17Initiated RBC Capital Mkts Outperform $58
Mar-16-17Initiated Oppenheimer Perform
Feb-10-17Downgrade BofA/Merrill Neutral → Underperform
Dec-12-16Downgrade Credit Suisse Outperform → Neutral
Dec-06-16Reiterated RBC Capital Mkts Outperform $62 → $72
Oct-10-16Reiterated RBC Capital Mkts Outperform $55 → $62
Sep-15-16Upgrade Goldman Sell → Neutral
Sep-07-16Initiated Morgan Stanley Overweight
Jul-27-16Reiterated SunTrust Neutral $34 → $38
Jul-27-16Reiterated RBC Capital Mkts Outperform $125 → $130
Jul-27-16Reiterated Barclays Overweight $48 → $53
Jul-27-16Downgrade Cantor Fitzgerald Buy → Hold
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $34
Feb-16-18 08:00AM  Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period Business Wire
Feb-15-18 07:48AM  Seattle Genetics Inc (SGEN) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Feb-14-18 12:14PM  Here's Why Pieris Pharmaceuticals Inc. Is Tanking Motley Fool
08:30AM  PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates PR Newswire
Feb-12-18 07:20AM  Wired News Pieris Pharma Collaborated with Seattle Genetics to Develop Immuno-Oncology Treatments ACCESSWIRE
Feb-09-18 12:50PM  Why Pieris Pharmaceuticals Inc. Is Soaring Today Motley Fool
06:45AM  Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration Business Wire
06:45AM  Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration Marketwired
Feb-08-18 05:39PM  Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. Business Wire
04:14PM  Seattle Genetics Is Growing Up Any Way It Can Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Array BioPharma Inc. and Seattle Genetics ACCESSWIRE
Feb-07-18 10:59AM  Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates Zacks
Feb-06-18 05:55PM  Seattle Genetics reports 4Q loss Associated Press
04:02PM  Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results Business Wire
12:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-18 09:46AM  The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex Zacks
08:50AM  Why Earnings Season Could Be Great for Seattle Genetics (SGEN) Zacks
Feb-03-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-02-18 08:30AM  Seattle Genetics Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
08:20AM  Todays Research Reports on Trending Tickers: Nektar Therapeutics and Seattle Genetics, Inc. ACCESSWIRE
07:20AM  Wired News Seattle Genetics to Acquire Cascadian Therapeutics ACCESSWIRE
Feb-01-18 04:02PM  Biotech Roundup: Who's Popping On Drug, Merger, Earnings News? Investor's Business Daily +7.36%
08:03AM  Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition Market Exclusive
07:48AM  Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi Zacks
06:30AM  Seattle Genetics Announces Pricing of Public Offering of Common Stock Business Wire
Jan-31-18 03:22PM  Here's Why Cascadian Therapeutics Jumped Up to 73.1% Today Motley Fool -5.27%
11:34AM  Why Cascadian Therapeutics Inc (USA) Is Todays Best Biotech Stock SmarterAnalyst
11:00AM  Why Cascadian Therapeutics Shares Are Skyrocketing 24/7 Wall St.
08:42AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
06:40AM  Seattle Genetics Announces Proposed Public Offering of Common Stock Business Wire
06:30AM  Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline Business Wire
Jan-26-18 09:30AM  Seattle Genetics Adcetris Performs Well Despite Competition Zacks
Jan-23-18 05:10PM  Key Updates on Novartiss Kymriah Market Realist
03:39PM  How Is Novartiss Kymriah Positioned for 2018? Market Realist
09:44AM  Seattle Genetics' Adcetris Gets EU Nod for Label Expansion Zacks
Jan-22-18 08:00AM  Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy Business Wire +5.25%
Jan-19-18 10:32AM  Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb Market Realist
Jan-18-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018 Business Wire
Jan-08-18 07:00PM  Cramer's lightning round: Mercadolibre is even better tha... CNBC Videos
06:50PM  Cramer's lightning round: Mercadolibre is even better than eBay was CNBC
08:08AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-05-18 09:48AM  Cancer Space Update: New Regulatory Status for 3 Major Drugs Zacks
08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Jan-04-18 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:04AM  Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer Zacks
Jan-03-18 01:33PM  Seattle Genetics' Adcetris sBLA Gets FDA Priority Review Zacks
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
Dec-28-17 12:40PM  ETFs with exposure to Seattle Genetics, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:44AM  Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-19-17 08:00AM  Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-15-17 08:00AM  Todays Research Reports on Trending Tickers: Juno Therapeutics and Seattle Genetics ACCESSWIRE
Dec-11-17 01:06PM  Why Seattle Genetics, Inc. Fell Today Motley Fool -6.74%
10:30AM  Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma Business Wire
Dec-10-17 06:33PM  Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
09:00AM  Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting Business Wire
Dec-09-17 09:00AM  Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting Business Wire
Dec-08-17 08:07AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
Dec-07-17 08:00AM  Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium Business Wire
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool
Dec-04-17 09:03AM  What Analysts Recommend for United Therapeutics in November 2017 Market Realist
08:00AM  Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting Business Wire
07:30AM  Market-Moving News Is on Tap for Seattle Genetics Motley Fool
Dec-01-17 08:10AM  Todays Research Reports on Stocks to Watch: Seattle Genetics and Alnylam Pharmaceuticals ACCESSWIRE
Nov-29-17 03:56AM  Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report? Zacks
Nov-28-17 07:52AM  Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 28, 2017 Capital Cube
Nov-15-17 01:17PM  Seattle Genetics, Inc. Value Analysis (NASDAQ:SGEN) : November 15, 2017 Capital Cube
Nov-14-17 10:26AM  Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 14, 2017 Capital Cube
Nov-13-17 09:41AM  Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion Zacks
Nov-10-17 08:30AM  Report: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-09-17 12:40PM  Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) Business Wire
Nov-08-17 08:00AM  Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Nov-02-17 08:00AM  Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
07:40AM  Earnings Review and Free Research Report: Biogens Adjusted EPS Surged 25.1% ACCESSWIRE
Nov-01-17 02:17PM  Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come Motley Fool
09:00AM  Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017 Business Wire
07:10AM  Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer ACCESSWIRE
Oct-30-17 03:00AM  IBD Rating Upgrades: Seattle Genetics Flashes Improved Price Strength Investor's Business Daily
01:45AM  Edited Transcript of SGEN earnings conference call or presentation 26-Oct-17 8:30pm GMT Thomson Reuters StreetEvents
Oct-27-17 11:42AM  Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat Zacks
09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com
Oct-26-17 05:29PM  Seattle Genetics tops Street 3Q forecasts Associated Press
04:02PM  Seattle Genetics Reports Third Quarter 2017 Financial Results Business Wire
09:40AM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Oct-25-17 01:04PM  [$$] Seattle Genetics May See 'Significant Upside' Barrons.com
08:58AM  Should You Sell Seattle Genetics (SGEN) Before Earnings? Zacks
Oct-19-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Oct-13-17 07:13PM  Cramers Exec Cut: CEO reveals his companys plans to dis... CNBC Videos
11:18AM  Cancer Space Update: Lung & Breast Cancer Studies in Focus Zacks
Oct-12-17 10:18AM  Seattle Genetics Inks Clinical Collaborations for Cancer Drug Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics ACCESSWIRE
Oct-11-17 07:10PM  Cramer Remix: Its not about sex appeal, its about timin... CNBC Videos +6.51%
07:02PM  Seattle Genetics CEO talks new cancer treatment pipeline,... CNBC Videos
06:59PM  Cramer Remix: Its not about sex appeal, its about timing CNBC
05:03PM  Why Snap, Seattle Genetics, and Pretium Resources Jumped Today Motley Fool
04:38PM  This Drugmaker Hit A 4-Month High On Collaboration With Dow's Merck Investor's Business Daily
10:29AM  Seattle Genetics Begins Phase II Study of Cancer Candidate Zacks
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WELCH DANIEL GDirectorFeb 13Option Exercise9.3916,881158,46366,100Feb 15 09:21 PM
SIEGALL CLAY BPresident and CEOFeb 09Option Exercise11.0918,832208,847697,546Feb 13 08:19 PM
SIEGALL CLAY BPresident and CEOFeb 09Sale49.7518,832936,818687,146Feb 13 08:19 PM
BAKER BROS. ADVISORS LPDirectorFeb 01Buy52.003,846,153199,999,95644,355,335Feb 05 04:00 PM
SIEGALL CLAY BPresident and CEOJan 11Option Exercise11.0918,832208,847697,716Jan 16 08:08 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJan 11Option Exercise11.0619,416214,705170,934Jan 16 08:04 PM
SIEGALL CLAY BPresident and CEOJan 11Sale51.7118,832973,873687,146Jan 16 08:08 PM
SIEGALL CLAY BPresident and CEODec 11Option Exercise11.0918,832208,847698,933Dec 13 08:50 PM
SIEGALL CLAY BPresident and CEODec 11Sale55.4018,8321,043,329687,146Dec 13 08:50 PM
DOBMEIER ERICChief Operating OfficerDec 04Option Exercise32.006,165197,300121,153Dec 06 08:04 PM
DOBMEIER ERICChief Operating OfficerDec 04Sale58.753,729219,092117,424Dec 06 08:04 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.1610,000121,573172,306Dec 04 07:54 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale59.9710,000599,729164,906Dec 04 07:54 PM
DOBMEIER ERICChief Operating OfficerNov 17Option Exercise26.1010,000261,000127,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 17Sale59.1310,000591,250117,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 16Option Exercise20.2315,400311,617125,913Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 16Sale57.9615,400892,637117,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 15Option Exercise15.469,600148,416127,024Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 15Sale57.809,600554,837117,424Nov 17 08:45 PM
LIPPMAN MARC EDirectorNov 15Sale58.073,000174,224132,050Nov 17 08:47 PM
SIEGALL CLAY BPresident and CEONov 10Option Exercise11.0918,832208,847704,255Nov 14 07:40 PM
SIEGALL CLAY BPresident and CEONov 10Sale58.0018,8321,092,193687,146Nov 14 07:40 PM
SIMPSON TODD EChief Financial OfficerNov 01Sale60.9139,3852,398,915178,992Nov 03 05:42 PM
SIEGALL CLAY BPresident and CEOOct 11Option Exercise11.0918,832208,847694,045Oct 13 08:58 PM
SIEGALL CLAY BPresident and CEOOct 11Sale61.1818,8321,152,234687,146Oct 13 08:58 PM
DRACHMAN JONATHAN GCMO & EVP, R & DOct 05Option Exercise11.5217,816205,253151,518Oct 10 06:42 PM
SIEGALL CLAY BPresident and CEOSep 26Option Exercise11.099,01799,999687,146Sep 28 06:15 PM
SIEGALL CLAY BPresident and CEOSep 11Option Exercise11.0918,832208,847695,246Sep 12 07:34 PM
SIEGALL CLAY BPresident and CEOSep 11Sale53.4918,8321,007,257678,129Sep 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerSep 08Option Exercise11.2310,000112,329171,742Sep 12 07:32 PM
HIMES VAUGHN BChief Technical OfficerSep 08Sale53.2210,000532,190164,906Sep 12 07:32 PM
Cline Darren SEVP, CommercialSep 06Option Exercise15.9410,048160,11582,254Sep 08 07:32 PM
SIMPSON TODD EChief Financial OfficerSep 06Sale52.009,638501,176218,377Sep 08 07:34 PM
Cline Darren SEVP, CommercialSep 06Sale51.945,024260,96777,230Sep 08 07:32 PM
Cline Darren SEVP, CommercialAug 31Option Exercise18.462,90753,66379,775Sep 05 07:23 PM
DOBMEIER ERICChief Operating OfficerAug 31Option Exercise15.4625,000386,500142,424Sep 05 07:25 PM
DOBMEIER ERICChief Operating OfficerAug 31Sale52.2425,0001,305,893117,424Sep 05 07:25 PM
Cline Darren SEVP, CommercialAug 31Sale52.517,569397,46672,206Sep 05 07:23 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale47.894,937236,455228,015Aug 30 07:27 PM
SIEGALL CLAY BPresident and CEOAug 28Sale47.8925,5061,221,597678,129Aug 30 07:25 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale47.896,377305,423164,906Aug 30 07:24 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 28Sale47.898,502407,199133,702Aug 30 07:23 PM
DOBMEIER ERICChief Operating OfficerAug 28Sale47.895,343255,900117,424Aug 30 07:21 PM
Cline Darren SEVP, CommercialAug 28Sale47.891,78885,63576,868Aug 30 07:18 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 24Option Exercise10.2910,000102,900152,204Aug 25 07:52 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 24Sale47.5410,000475,414142,204Aug 25 07:52 PM
Cline Darren SEVP, CommercialAug 07Option Exercise18.466,000110,76067,656Aug 09 06:52 PM
SIEGALL CLAY BPresident and CEOAug 07Option Exercise10.2910,413107,150646,848Aug 09 06:58 PM
SIEGALL CLAY BPresident and CEOAug 07Sale48.9110,413509,300636,435Aug 09 06:58 PM
Cline Darren SEVP, CommercialAug 07Sale49.196,000295,11061,656Aug 09 06:52 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJul 27Option Exercise10.2910,000102,900125,204Jul 31 07:15 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJul 27Sale54.5410,000545,361115,204Jul 31 07:15 PM
SIEGALL CLAY BPresident and CEOJul 05Option Exercise10.2910,423107,253644,629Jul 07 07:20 PM
SIEGALL CLAY BPresident and CEOJul 05Sale51.9810,423541,807636,435Jul 07 07:20 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJun 22Option Exercise10.2910,000102,900125,204Jun 26 06:25 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJun 22Sale64.0110,000640,058115,204Jun 26 06:25 PM
SIEGALL CLAY BPresident and CEOJun 05Option Exercise10.2910,423107,253646,195Jun 07 07:24 PM
SIEGALL CLAY BPresident and CEOJun 05Sale65.2110,423679,698636,435Jun 07 07:24 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise9.2310,00092,300160,683Jun 02 07:08 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale62.5910,000625,922151,283Jun 02 07:08 PM
BAKER BROS. ADVISORS LPDirectorMay 15Option Exercise10.2020,000204,00040,895,092May 17 05:26 PM
SIEGALL CLAY BPresident and CEOMay 05Option Exercise10.2614,462148,450645,765May 09 07:42 PM
SIEGALL CLAY BPresident and CEOMay 05Sale61.7414,462892,897636,435May 09 07:42 PM
SIEGALL CLAY BPresident and CEOApr 05Option Exercise10.2614,465148,481646,858Apr 06 08:10 PM
SIEGALL CLAY BPresident and CEOApr 05Sale62.9914,465911,111636,435Apr 06 08:10 PM
HIMES VAUGHN BChief Technical OfficerMar 31Option Exercise9.2310,00092,300161,283Apr 04 05:48 PM
HIMES VAUGHN BChief Technical OfficerMar 31Sale62.7510,000627,527151,283Apr 04 05:48 PM
SIEGALL CLAY BPresident and CEOMar 06Option Exercise10.2614,465148,481646,858Mar 08 07:22 PM
SIEGALL CLAY BPresident and CEOMar 06Sale68.0414,465984,259636,435Mar 08 07:22 PM